NEW YORK, Aug. 1, 2017 /PRNewswire/ -- About Retinal Drugs
Ophthalmic disorders largely consist of minor disorders that need minimal or no treatment, however, few other disorders become critical in nature and need specialist care. A delay in treatment in case of critical disorders may even lead to vision loss.
Read the full report: http://www.reportlinker.com/p05006318/Global-Retinal-Drugs-Market.html
Retinal disorders, glaucoma, dry-eye, infection/inflammation in the eyes, and allergic/otic problems are the major ophthalmic disorders. The retinal drugs market holds the largest share of the global ophthalmic disorder treatment market, followed by glaucoma treatment drugs market. The global retinal drugs market is expected to grow with a high CAGR of 11.66% due to the high demand of age-related macular degeneration (AMD) drugs and diabetic eye disease drugs. This is due to the rising geriatric population and an increase in the population with diabetes. Also, countries across the globe are investing significantly in the healthcare sector. This has, in turn, increased awareness and diagnosis rate of the disease.
Technavio's analysts forecast the global retinal drugs market to grow at a CAGR of 11.66% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global retinal drugs market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs in retinal disorders market.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Retinal Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bayer
• F. Hoffmann-La Roche
• Novartis
• Regeneron
Other prominent vendors
• Merck
• Shire
• Teva Pharmaceutical
• ThromboGenics
Market driver
• Rising geriatric population and corresponding increase in patient pool
• For a full, detailed list, view our report
Market challenge
• Shortage of trained professionals
• For a full, detailed list, view our report
Market trend
• Rising use of combination therapies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.
Read the full report: http://www.reportlinker.com/p05006318/Global-Retinal-Drugs-Market.html
About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.
http://www.reportlinker.com
__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001
SOURCE Reportlinker
Related Links
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article